For Immediate Release

Chicago, IL – April 8, 2010 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Monsanto Company (MON), Keryx Biopharmaceuticals (KERX), Sanofi-Aventis (SNY), Roche (RHHBY) and Pfizer (PFE).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter:

Here are highlights from Wednesday’s Analyst Blog:

Monsanto Surpasses Zacks Estimate

Monsanto Company (MON) announced results for the second quarter of fiscal 2010. During the quarter, net income decreased to $887 million from $1,092 million in the same quarter of 2008.

EPS (excluding a restructuring expense) was $1.70 compared to $2.16 in the year-ago quarter. The decrease was due to a fall in revenue and gross margin. However, the reported EPS was above the Zacks Consensus Estimate of $1.66.

Revenue decreased 3.6% to $3,890 million from $4,035 million during the same period in the previous year. Decrease in revenue was attributable to fall in prices of glyphosate-based herbicides produced by the company.

Keryx Gets Fast-Track Status

Keryx Biopharmaceuticals (KERX) received fast track status from the US Food and Drug Administration (FDA) for KRX-0401 (perifosine), which is being studied for treating refractory advanced colorectal cancer. This status is granted to drugs with the potential to treat serious or fatal conditions and qualify for a faster review process.

Keryx plans to initiate a phase III trial of perifosine in the second quarter of 2010 under the FDA’s Special Protocol Assessment (SPA) program. The trial aims at comparing perifosine in combination with capecitabine (Xeloda) versus placebo plus capecitabine in patients with refractory advanced colorectal cancer. The study is expected to be completed in the second half of 2011. Keryx plans to launch the drug by mid 2012.

Although perifosine is the lead candidate at Keryx, it is also developing Zerenex (ferric citrate), which has completed a phase II study for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with final-stage renal disease. The phase III trial is yet to begin under an SPA agreement with the FDA.

Apart from colorectal cancer, perifosine is being studied in a phase III trial under an SPA for the treatment of relapsed/refractory multiple myeloma. Keryx has orphan drug status and fast track designation for this study. Keryx does not have any marketed product at present and is heavily dependent on the successful commercialization of perifosine.

Despite the presence of many products such as Sanofi-Aventis’ (SNY) Eloxatin (oxaliplatin), Roche’s (RHHBY) Avastin (bevacizumab), Merck KGaA’s Erbitux (cetuximab), Pfizer’s (PFE) Camptosar (irinotecan) in the field of colorectal cancer, the demand remains still unmet. According to the American Cancer Society, colorectal cancer is the third most common form of cancer diagnosed in the US with over 49,000 casualties in 2009.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter:

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks “Profit from the Pros” e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today:

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Mark Vickery
Web Content Editor



Zacks Investment Research